Summary
Ribonucleotide reductase is the rate limiting enzyme of deoxynucleoside triphosphate synthesis and is considered to be an excellent target of cancer chemotherapy. Didox and amidox are newly synthesized compounds, which inhibit this enzyme and have in vitro and in vivo antitumor activity. We have now investigated the capability of didox and amidox to interfere with the iron metabolism. We show by photometric and polarographic methods, that didox and amidox are capable of forming an iron complex. However, their cytotoxic action cannot be circumvented by addition of Fe-ammoniumcitrate, indicating the iron com-plexing capacity not to be responsible for the mechanism of action of these compounds. When L1210 leukemia cells were incubated with the didox-iron or amidox-iron complex itself, only slight changes of the 50% growth inhibitory capacity of the complex in comparison with didox or amidox alone could be shown. We conclude, that didox and amidox are capable of forming an iron complex, but in contrast to other agents, the anticancer activity cannot be contributed to this effect alone. Further studies will have to elucidate the molecular mechanism of action of these new and promising anticancer agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G. Weber, New Engl. J. Med. 296 486–93 (1977).
E. Takeda and G. Weber, Life Sci. 28 1007–14 (1981).
H.L. Elford, M. Freese, M. Passamani, H.P. Morris, J. Biol. Chem. 245 5228–33 (1970).
J.G. Cory, G.L. Carter, Advan. Enzyme Regul. 24 385–401 (1985).
J.G. Cory, Advan. Enzyme Regul. 27 437–55 (1988).
H.L. Elford, B. Vant Riet, G.L. Wampler, A.L. Lin, R.M. Elford, Advan. Enzyme Regul. 19 151–68 (1981).
H.L. Elford, G.L. Wampler, B. Vant Riet, Cancer Res. 39 844–51 (1979).
B. Vant Riet, L.B. Kier, H.L. Elford, J. Pharm. Sci. 69 856–7 (1980).
H.L. Elford, B. Vant Riet, G.L. Wampler, U.S. patent 4623659 United States Patent Office. Washington, D.C. (1986).
D. Veale, J. Carmichael, B.M.J. Cantwell, H.L. Elford, R. Blackie, D.J. Kerr, S.B. Kaye, A.L. Harris, Br. J. Cancer. 58 70–72 (1988).
R.D. Rubens, S.B. Kaye, M. Soukop, C.J. Williams, M.H. Brampton, A.L. Harris, Br. J. Cancer. 64, 1187–1188 (1991).
T. Szekeres, E. Vielnascher, L. Novotny, A. Vachalkova, M. Fritzer, G. Findenig, R. Goebl, H.L. Elford, H. Goldenberg, Eur. J. Clin. Chem. Clin. Biochem. 33 785–789 (1995).
J. Narasimhan, W.E. Antholine, C.R. Chitambar, Biochem. Pharmacol. 44 2403–2408 (1992).
T. Szekeres, M. Fritzer, H. Strobl, K. Gharehbaghi, G. Findenig, H.L. Elford, C. Lhotka, H.J. SchÖN and H.N. Jarayam, Blood. 84 4316–21 (1994).
H.L. Elford, B. Vant Riet, E.A. Mikhail, J.L. Zweier, Proc. Am. Ass. Cancer Res. 36 296 (ab-stract)(1995).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Fritzer-Szekeres, M., Novotny, L., Vachalkova, A., Göbl, R., Elford, H.L., Szekeres, T. (1998). Iron Binding Capacity of Didox (3,4 Dihydroxybenzohydroxamic Acid) and Amidox (3,4 Dihydroxybenzamidoxime) two Inhibitors of the Enzyme Ribonucleotide Reductase. In: Griesmacher, A., Müller, M.M., Chiba, P. (eds) Purine and Pyrimidine Metabolism in Man IX. Advances in Experimental Medicine and Biology, vol 431. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5381-6_116
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5381-6_116
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7456-5
Online ISBN: 978-1-4615-5381-6
eBook Packages: Springer Book Archive